Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod

被引：0
|
作者：
Zhang, Peijin [1 ]
Hosein, Fareeda [1 ]
Yu, Kyungha [1 ]
Walker, Susan [1 ]
Syto, Mary [1 ]
Tirucherai, Giridhar [1 ]
Murthy, Bindu [1 ]
Tatosian, Daniel [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1532/314
引用
收藏
页码：976 / 976
页数：1
相关论文
共 50 条
  • [31] EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE SAFETY AND PHARMACOKINETICS OF REZAFUNGIN
    Ong, Voon
    Sandison, Taylor
    Melara, Rebeca
    Marbury, Thomas
    Huguet, Jade
    Jandourek, Alena
    Flanagan, Shawn
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 334 - 334
  • [32] Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment
    Venkatakrishnan, Karthik
    Liu, Yi
    Noe, Dennis
    Mertz, Jaime
    Bargfrede, Michael
    Marbury, Thomas
    Farbakhsh, Kambiz
    Oliva, Cristina
    Milton, Ashley
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) : 998 - 1010
  • [33] Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment
    Turncliff, RZ
    Dunbar, JL
    Dong, QM
    Silverman, BL
    Ehrich, EW
    Dilzer, SC
    Lasseter, KC
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (11): : 1259 - 1267
  • [34] Effect of moderate hepatic impairment and cigarette smoking on the pharmacokinetics of istradefylline
    Rao, N.
    Chaikin, P.
    Dvorchik, B.
    Sussman, N.
    Mori, A.
    Uchimura, T.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S104 - S104
  • [35] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    Frost, C. E.
    Yu, Z.
    Wang, J.
    Li, T.
    Zeigler, C.
    Schuster, A.
    Ly, V.
    Zhang, D.
    LaCreta, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
  • [36] Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment
    Rolfo, Christian
    Isambert, Nicolas
    Italiano, Antoine
    Molife, L. Rhoda
    Schellens, Jan Hm
    Blay, Jean-Yves
    Decaens, Thomas
    Kristeleit, Rebecca
    Rosmorduc, Olivier
    Demlova, Regina
    Lee, Myung-Ah
    Ravaud, Alain
    Kopeckova, Katerina
    Learoyd, Maria
    Bannister, Wendy
    Locker, Gershon
    de Vos-Geelen, Judith
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) : 1807 - 1818
  • [37] EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF AFICAMTEN AND ITS METABOLITES.
    Xu, D.
    Divanji, P.
    Kim, E.
    Li, J.
    Benattia, Y.
    Griffith, A.
    Kupfer, S.
    German, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S8 - S9
  • [38] Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
    Chevalier, Clemence
    Dubourg, Julie
    Bolze, Sebastien
    Fouqueray, Pascale
    CLINICAL PHARMACOKINETICS, 2021, 60 (04) : 485 - 490
  • [39] Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
    Clémence Chevalier
    Julie Dubourg
    Sébastien Bolze
    Pascale Fouqueray
    Clinical Pharmacokinetics, 2021, 60 : 485 - 490
  • [40] Pharmacokinetics of islatravir in participants with moderate hepatic impairment
    Matthews, Randolph P.
    Patel, Munjal
    Liu, Wen
    Liu, Yang
    Rondon, Juan C.
    Vargo, Ryan C.
    Stoch, S. Aubrey
    Iwamoto, Marian
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025,
12345